补肾解毒通络法对慢性肾衰模型干预作用的理论与实验研究
|
摘要
目的在中医理论的指导下,结合“络脉络病理论”,探讨慢性肾衰的基本病机及其治疗方法和方药组成,并通过动物实验深入研究补肾解毒通络法的作用机理,为补肾解毒通络法在临床上的应用提供初步的实验依据。本文主要由理论探讨、实验研究和结论与探讨三大部分组成。
理论探讨1、慢性肾衰的基本病机是肾虚络痹毒结。(1)肾脏亏虚是慢性肾衰发病的根本：肾藏精,为脏腑阴阳之本、生命之源,称其为“先天之本”。先天之本衰败,则容易受到内外邪气的侵袭,而邪气乘虚而入,日久化火灼阴,化热积毒,阻于肾络,影响肾的生理功能,从而导致慢性肾衰的发病。(2)络痹毒结是慢性肾衰的病理关键：肾病日久,肾脏亏虚一方面使其化生精微物质的能力下降,精亏血少,从而导致肾络失养,络病产生。另一方面使络中气血循环的动力下降,使病邪留滞,痰、瘀、毒形成,淤阻于肾络,导致络痹毒结。而肾络是气血营养肾脏的关键和枢纽,肾络畅、气血充,则肾脏得养而功能健旺；肾络痹、气血虚,则肾脏失养而功能衰竭。所以肾脏亏虚是慢性肾衰发病的根本,但是络痹毒结是其病理关键。(3)肾虚与络痹毒结相互影响,互为因果：慢性肾衰病程长,演变多,首先是肾脏功能受损,随着病情发展而波及脾胃、三焦、肝、心和肺等脏腑,导致五脏六腑的气血阴阳俱虚,但肾脏亏虚是其发病的关键。同时,肾虚导致肾络不荣,影响其运行气血、渗灌濡养等功能,使得气血虚滞不畅而致瘀血内生、津凝化痰、化热积毒,痹阻络脉。而肾络痹阻又影响着络中气血生化之机,从而加重肾虚,如此循环往复,加重病情。可见,在慢性肾衰的整个病程中,脏虚和络痹毒结相互影响,互为因果。2、补肾解毒通络法是治疗慢性肾衰的重要治法。肾虚络痹毒结是慢性肾衰的基本病机,因此,慢性肾衰的重要治法则是补肾解毒通络法。慢性肾衰的病情反复,虚实夹杂,故治当标本兼治,通补兼施,寓通于补,通不致虚,补不留邪,调理气血,恢复脏腑功能,冀使虚复、瘀除、痰祛、毒解。3、组方依据与方药分析。“补肾解毒通络法”的代表方剂为“补肾解毒通络方”,该方组成为：黄芪30g、淫羊藿20g、山茱萸15g、丹参30g、地龙15g、金银花15g、大黄6g。其中,黄芪合淫羊藿,补肾益气,共为君药；山茱萸、丹参、地龙、金银花,补肾、益气、化瘀、解毒、通络,共为臣药；大黄清热解毒、活血祛瘀,为佐使。全方合用,共奏补肾益气、清热解毒、活血通络之功。
实验研究方法：按照文献方法采用腺嘌呤灌胃制作大鼠慢性肾衰模型。并在此基础上应用补肾解毒通络方开展对模型进行干预作用的实验研究。将SPF级雄性Wistar大鼠40只随机分为正常对照组(10只)和模型组(30只)进行模型制作。而后将造模成功的29只大鼠随机分为模型对照组、尿毒清组和补肾解毒通络方组分别进行给药干预。给药结束后,检测每组大鼠血肌酐、血尿素氨和转化生长因子-β1、肾组织Ⅰ型胶原、骨形态发生蛋白-7及其三者mRNA的表达。结果：1、血肌酐和血尿素氮：模型组和治疗各组BUN、Scr水平与正常组比均显著升高,有非常显著性差异(P<0.01)。尿毒清组、中药治疗组与模型组相比,BUN、Scr水平均显著降低,有非常显著性差异(P<0.01)。其中,中药治疗组BUN低于尿毒清组(P<0.05),而Scr值两者无显著性差异(P>0.05)。2、大鼠肾组织中Col-I蛋白的表达：与正常组相比,模型组、尿毒清组和中药治疗组Colla-Ⅰ蛋白的表达均显著增高,有非常显著性差异(P<0.01)。尿毒清组、中药治疗组能够抑制Colla-Ⅰ蛋白的表达,与模型组相比均显著降低,有非常显著性差异(P<0.01)。其中,中药治疗组低于尿毒清组,两者有显著性差异(P<0.01,P<0.05)。3、大鼠肾组织中TGF-β1蛋白的表达：与正常组相比,模型组、尿毒清组和中药治疗组TGF-β1蛋白的表达均显著增高,有非常显著性差异(P<0.01)。尿毒清组、中药治疗组能够抑制TGF-β1蛋白的表达,与模型组相比均有显著性差异(P<0.01,P<0.05)。其中,中药治疗组低于尿毒清组,两者有显著性差异(P<0.01,P<0.05)。4、大鼠肾组织中BMP-7蛋白的表达：与正常组相比,模型组、尿毒清组和中药治疗组BMP-7的表达均显著降低,有非常显著性差异(P<0.01)。尿毒清组、中药治疗组BMP-7的表达与模型组相比均显著增高,有非常显著性差异(P<0.01)。其中,中药治疗组高于尿毒清组,两者有显著性差异(P<0.01,P<0.05)。5、大鼠肾组织Col-ImRNA的表达：与正常组相比,模型组、尿毒清组和中药治疗组Colla-ImRNA的表达均增高,有显著性差异(P<0.05)。尿毒清组和中药治疗组Colla-ImRNA的表达低于模型组,与模型组相比均有显著性差异(P<0.05)。其中,中药治疗组Colla-ImRNA的表达低于尿毒清组(P<0.05)。6、大鼠肾组织中TGF-β1mRNA的表达：与正常组相比,模型组、尿毒清组和中药治疗组TGF-β11mRNA的表达均增高,有显著性差异(P<0.05)。尿毒清组和中药治疗组TGF-β1mRNA的表达低于模型组,与模型组相比均有显著性差异(P<0.05)。其中,中药治疗组TGF-β1mRNA的表达低于尿毒清组(P<0.05)。7、大鼠肾组织中BMP-7mRNA的表达：与正常组相比,模型组、尿毒清组和中药治疗组BMP-7mRNA的表达均降低,有显著性差异(P<0.05)。尿毒清组、中药治疗组BMP-7mRNA的表达与模型组相比均增高,有显著性差异(P<0.05)。其中,中药治疗组高于尿毒清组,两者有显著性差异(P<0.05)。
结论：1、补肾解毒通络方可以减轻慢性肾衰大鼠的肾功能损伤。2、补肾解毒通络方可以减轻慢性肾衰大鼠的病理损伤,且效果优于尿毒清颗粒。3、补肾解毒通络方通过降低慢性肾衰大鼠肾组织中Col-Ⅰ、TGF-β1及其两者mRNA的表达,增高BMP-7和BMP-7mRNA的表达而减轻肾间质纤维化可能是其起延缓慢性肾衰进展的机制之一。4、补肾解毒通络方在影响Col-Ⅰ、TGF-β1、BMP-7及其三者mRNA的表达方面效果均优于尿毒清颗粒。
Objective Probing the basic pathogenesis of chronic renal failure, its therapeutic methods and the composition of herbs under the direction of traditional chinese medicine theory combined with collateral disease theory, then through animal experiments to study the mechanism of the Bushen Jiedu Tongluo act, so as to effort warranty of the experiment for clinical application.The text was divided into three parts:theory probing, experiment al study and conclusion.
Theory probing 1The basic pathogenesis of chronic renal failure is asthenia of kidney, venation obstruction and toxic factors accumulating in tissue. (1)The primary aspect of chronic renal failure is asthenia of kidney: kidney storing essence, being the organs of the yin and yang and trials of life.We call it"a priori of the present". Kidney deficiency and it vulnerable to the attack of internal-external influences, So evil can infiltrate by taking advantage of the other side's unpreparedness, hurt Yin and accumulate poison for a long time which could obstruct kidney network, it affect various physiological function and structure of the kidney which lead to the incidence of chronic renal failure. (2) Venation obstruction and toxic factors accumulating in tissue are the pathological basis of chronic renal failure:Kidney is a priori of the present. On the one hand, insufficiency of kidney-qi cause the function of producing microscopic materials reduced, the kidney-essence and blood decreased, as that the kidney network dystrophy cause the function of communicating exterior and interior, infiltrating blood and fluids, and excreting body wastes reduced which lead kidney network malnutrition and collateral disease generate. On the other hand, it cause the power of blood circulation down which lead turbid phlegm, blood stasis and pathogenic toxin obstruct the kidney network. While the renal collaterals is the key and the hub of qi and blood for renal nutrition.If renal collaterals is clear, qi and blood is sufficient, then the kidney function was to support the healthy and vigorous; if renal collaterals is not clear, qi and blood is deficiency, kidney failure is the failure to support. (3) The two which is asthenia of kidney and which is venation obstruction and toxic factors accumulating in tissue interact, reinforce each other:chronic renal failure disease process is various reasons causes kidney damaged, so we lost two division, San Jiao damaged, the function of separating the clear from turbid decreased, damp turbidity and uremia can not be eliminated from the body while accumulate in the body which lead to venation obstruction. In turn, toxic factors accumulating in tissue injury righteousness, block air machine, increase the network weakness, so on and so on, adding condition.2. The main treatment of chronic renal failure is nourishing the kidney as well as removing toxic materials and dredging collaterals according to the pathogenesis:TCM establish treatment principles according to etiology, pathogenesis and pathological changes. The basic pathogenesis of chronic renal failure is asthenia of kidney, venation obstruction and toxic factors accumulating in tissue, so the main treatment of chronic renal failure is nourishing the kidney as well as removing toxic materials and dredging collaterals. Relapse of chronic renal failure cause that its treatment focuses on both the root and branch aspects, supporting healthy qi and removing pathogenic factors. So as that we can tonify deficiency, activate the blood, dissolve phlegm and detoxication.3 Prescription basis and recipe analysis:Prescription of Bushen Jiedu Tongluo act representative for the Bushen Jiedu Tongluo recipe which consisting of:astragalus 30g, epimedium 20g, fructus corni 15g, salvia miltiorrhiza 30g, earthworm 15g, honeysuckle 15g, rhubarb 6g. Meanwhile, astragalus and epimedium is monarch drug for reinforcing kidney and qi. Fructus corni, salvia miltiorrhiza, earthworm and honeysuckle is ministerial drug for reinforcing kidney and qi, removing blood stasis, expelling miasma, freeing channel. Rhubarb is assistant and guide for clearing heat and expelling miasma, promoting blood circulation by removing blood stasis. All side effects for tonifying qi of the kidney, clearing away heat and toxic material, activating blood and dredging collaterals.
Experimental study Methods:The chronic renal failure rat models were caused by adenine according to literature method. The SPF-class male Wistar rats were randomly divided into two groups:normal control group and model group. After the success of modeling, the rats in model group were randomly divided into three groups:model control group、Niaoduqing group and Bushen Jiedu Tongluo group. After administration respectively,we observed BUN、Scr、transforming growth factorβ1、collagen typeⅠ、bone morphogenetic protein 7、TGFβ1mRNA、col-ImRNA and BMP-7mRNA. Results:1BUN and Scr:The points of BUN、Scr in the model group and treatment groups was higher significantly compared with the normal group(P<0.01).The points of BUN、Scr in the Niaoduqing group and Bushen Jiedu Tongluo group was decreased compared with model control group(P<0.01). The points of BUN in the Bushen Jiedu Tongluo group was decreased compared with Niaoduqing group (P<0.05), while the points of Scr between them had no significant difference(P>0.05).2Col-I protein: The expression of col-I in the model group, Niaoduqing group and Bushen Jiedu Tongluo group was increased compared with the normal group(P<0.01). The expression of col-I in the Niaoduqing group and Bushen Jiedu Tongluo group was decreased compared with the Model group (P<0.01). Bushen Jiedu Tongluo group and Niaoduqing group had significant difference (P<0.01, P<0.05).3 TGF-β1 protein:The expression of TGF-β1 in the Model group, Niaoduqing group and Bushen Jiedu Tongluo group was increased compared with the normal group(P<0.01). The expression of TGF-β1 in the Niaoduqing group and Bushen Jiedu Tongluo group was decreased compared with the Model group (P<0.01, P<0.05). Bushen Jiedu Tongluo group and Niaoduqing group had significant difference (P<0.01, P<0.05).4 BMP-7 protein:The expression of BMP-7 in the Model group, Niaoduqing group and Bushen Jiedu Tongluo group was decreased compared with the normal group(P<0.01). The expression of BMP-7 in the Niaoduqing group and Bushen Jiedu Tongluo group was increased compared with the Model group (P<0.01). Bushen Jiedu Tongluo group and Niaoduqing group had significant difference (P<0.01, P<0.05).5Col-ImRNA:The expression of Col-ImRNA in the Model group, Niaoduqing group and Bushen Jiedu Tongluo group was increased compared with the normal group(P<0.05). The expression of Col-ImRNA in the Niaoduqing group and Bushen Jiedu Tongluo group was decreased compared with the Model group (P<0.05). Bushen Jiedu Tongluo group and Niaoduqing group had significant difference (P<0.05).6TGF-β1mRNA:The expression of TGF-β1mRNA in the Model group, Niaoduqing group and Bushen Jiedu Tongluo group was increased compared with the normal group(P<0.05). The expression of TGF-β1mRNA in the Niaoduqing group and Bushen Jiedu Tongluo group was decreased compared with the Model group (P<0.05). Bushen Jiedu Tongluo group and Niaoduqing group had significant difference (P<0.05).7BMP-7mRNA:The expression of BMP-7mRNA in the Model group, Niaoduqing group and Bushen Jiedu Tongluo group was decreased compared with the normal group(P<0.05). The expression of BMP-7mRNA in the Niaoduqing group and Bushen Jiedu Tongluo group was increased compared with the Model group (P<0.05). Bushen Jiedu Tongluo group and Niaoduqing group had significant difference(P<0.05). Conclusion lBushen Jiedu Tongluo recipe could reduce renal function in rats with chronic renal failure.2 Bushen Jiedu Tongluo recipe could reduce the pathological damage in rats with chronic renal failure, and it was better than Niaoduqing.3 Bushen Jiedu Tongluo recipe could alleviate chronic renal failure and reduce the renal interstitial fibrosis by reducing the expression of Col-I、TGF-β1、Col-I mRNA and TGF-β1mRNA, increasing the expression of BMP-7 and BMP-7mRNA.4 The side of expression of Col-I、TGF-β1、BMP-7、Col-I mRNA、TGF-β1mRNA and BMP-7mRNA effected by Bushen Jiedu Tongluo recipe was better than its by Niaoduqing.
理论探讨1、慢性肾衰的基本病机是肾虚络痹毒结。(1)肾脏亏虚是慢性肾衰发病的根本：肾藏精,为脏腑阴阳之本、生命之源,称其为“先天之本”。先天之本衰败,则容易受到内外邪气的侵袭,而邪气乘虚而入,日久化火灼阴,化热积毒,阻于肾络,影响肾的生理功能,从而导致慢性肾衰的发病。(2)络痹毒结是慢性肾衰的病理关键：肾病日久,肾脏亏虚一方面使其化生精微物质的能力下降,精亏血少,从而导致肾络失养,络病产生。另一方面使络中气血循环的动力下降,使病邪留滞,痰、瘀、毒形成,淤阻于肾络,导致络痹毒结。而肾络是气血营养肾脏的关键和枢纽,肾络畅、气血充,则肾脏得养而功能健旺；肾络痹、气血虚,则肾脏失养而功能衰竭。所以肾脏亏虚是慢性肾衰发病的根本,但是络痹毒结是其病理关键。(3)肾虚与络痹毒结相互影响,互为因果：慢性肾衰病程长,演变多,首先是肾脏功能受损,随着病情发展而波及脾胃、三焦、肝、心和肺等脏腑,导致五脏六腑的气血阴阳俱虚,但肾脏亏虚是其发病的关键。同时,肾虚导致肾络不荣,影响其运行气血、渗灌濡养等功能,使得气血虚滞不畅而致瘀血内生、津凝化痰、化热积毒,痹阻络脉。而肾络痹阻又影响着络中气血生化之机,从而加重肾虚,如此循环往复,加重病情。可见,在慢性肾衰的整个病程中,脏虚和络痹毒结相互影响,互为因果。2、补肾解毒通络法是治疗慢性肾衰的重要治法。肾虚络痹毒结是慢性肾衰的基本病机,因此,慢性肾衰的重要治法则是补肾解毒通络法。慢性肾衰的病情反复,虚实夹杂,故治当标本兼治,通补兼施,寓通于补,通不致虚,补不留邪,调理气血,恢复脏腑功能,冀使虚复、瘀除、痰祛、毒解。3、组方依据与方药分析。“补肾解毒通络法”的代表方剂为“补肾解毒通络方”,该方组成为：黄芪30g、淫羊藿20g、山茱萸15g、丹参30g、地龙15g、金银花15g、大黄6g。其中,黄芪合淫羊藿,补肾益气,共为君药；山茱萸、丹参、地龙、金银花,补肾、益气、化瘀、解毒、通络,共为臣药；大黄清热解毒、活血祛瘀,为佐使。全方合用,共奏补肾益气、清热解毒、活血通络之功。
实验研究方法：按照文献方法采用腺嘌呤灌胃制作大鼠慢性肾衰模型。并在此基础上应用补肾解毒通络方开展对模型进行干预作用的实验研究。将SPF级雄性Wistar大鼠40只随机分为正常对照组(10只)和模型组(30只)进行模型制作。而后将造模成功的29只大鼠随机分为模型对照组、尿毒清组和补肾解毒通络方组分别进行给药干预。给药结束后,检测每组大鼠血肌酐、血尿素氨和转化生长因子-β1、肾组织Ⅰ型胶原、骨形态发生蛋白-7及其三者mRNA的表达。结果：1、血肌酐和血尿素氮：模型组和治疗各组BUN、Scr水平与正常组比均显著升高,有非常显著性差异(P<0.01)。尿毒清组、中药治疗组与模型组相比,BUN、Scr水平均显著降低,有非常显著性差异(P<0.01)。其中,中药治疗组BUN低于尿毒清组(P<0.05),而Scr值两者无显著性差异(P>0.05)。2、大鼠肾组织中Col-I蛋白的表达：与正常组相比,模型组、尿毒清组和中药治疗组Colla-Ⅰ蛋白的表达均显著增高,有非常显著性差异(P<0.01)。尿毒清组、中药治疗组能够抑制Colla-Ⅰ蛋白的表达,与模型组相比均显著降低,有非常显著性差异(P<0.01)。其中,中药治疗组低于尿毒清组,两者有显著性差异(P<0.01,P<0.05)。3、大鼠肾组织中TGF-β1蛋白的表达：与正常组相比,模型组、尿毒清组和中药治疗组TGF-β1蛋白的表达均显著增高,有非常显著性差异(P<0.01)。尿毒清组、中药治疗组能够抑制TGF-β1蛋白的表达,与模型组相比均有显著性差异(P<0.01,P<0.05)。其中,中药治疗组低于尿毒清组,两者有显著性差异(P<0.01,P<0.05)。4、大鼠肾组织中BMP-7蛋白的表达：与正常组相比,模型组、尿毒清组和中药治疗组BMP-7的表达均显著降低,有非常显著性差异(P<0.01)。尿毒清组、中药治疗组BMP-7的表达与模型组相比均显著增高,有非常显著性差异(P<0.01)。其中,中药治疗组高于尿毒清组,两者有显著性差异(P<0.01,P<0.05)。5、大鼠肾组织Col-ImRNA的表达：与正常组相比,模型组、尿毒清组和中药治疗组Colla-ImRNA的表达均增高,有显著性差异(P<0.05)。尿毒清组和中药治疗组Colla-ImRNA的表达低于模型组,与模型组相比均有显著性差异(P<0.05)。其中,中药治疗组Colla-ImRNA的表达低于尿毒清组(P<0.05)。6、大鼠肾组织中TGF-β1mRNA的表达：与正常组相比,模型组、尿毒清组和中药治疗组TGF-β11mRNA的表达均增高,有显著性差异(P<0.05)。尿毒清组和中药治疗组TGF-β1mRNA的表达低于模型组,与模型组相比均有显著性差异(P<0.05)。其中,中药治疗组TGF-β1mRNA的表达低于尿毒清组(P<0.05)。7、大鼠肾组织中BMP-7mRNA的表达：与正常组相比,模型组、尿毒清组和中药治疗组BMP-7mRNA的表达均降低,有显著性差异(P<0.05)。尿毒清组、中药治疗组BMP-7mRNA的表达与模型组相比均增高,有显著性差异(P<0.05)。其中,中药治疗组高于尿毒清组,两者有显著性差异(P<0.05)。
结论：1、补肾解毒通络方可以减轻慢性肾衰大鼠的肾功能损伤。2、补肾解毒通络方可以减轻慢性肾衰大鼠的病理损伤,且效果优于尿毒清颗粒。3、补肾解毒通络方通过降低慢性肾衰大鼠肾组织中Col-Ⅰ、TGF-β1及其两者mRNA的表达,增高BMP-7和BMP-7mRNA的表达而减轻肾间质纤维化可能是其起延缓慢性肾衰进展的机制之一。4、补肾解毒通络方在影响Col-Ⅰ、TGF-β1、BMP-7及其三者mRNA的表达方面效果均优于尿毒清颗粒。
Objective Probing the basic pathogenesis of chronic renal failure, its therapeutic methods and the composition of herbs under the direction of traditional chinese medicine theory combined with collateral disease theory, then through animal experiments to study the mechanism of the Bushen Jiedu Tongluo act, so as to effort warranty of the experiment for clinical application.The text was divided into three parts:theory probing, experiment al study and conclusion.
Theory probing 1The basic pathogenesis of chronic renal failure is asthenia of kidney, venation obstruction and toxic factors accumulating in tissue. (1)The primary aspect of chronic renal failure is asthenia of kidney: kidney storing essence, being the organs of the yin and yang and trials of life.We call it"a priori of the present". Kidney deficiency and it vulnerable to the attack of internal-external influences, So evil can infiltrate by taking advantage of the other side's unpreparedness, hurt Yin and accumulate poison for a long time which could obstruct kidney network, it affect various physiological function and structure of the kidney which lead to the incidence of chronic renal failure. (2) Venation obstruction and toxic factors accumulating in tissue are the pathological basis of chronic renal failure:Kidney is a priori of the present. On the one hand, insufficiency of kidney-qi cause the function of producing microscopic materials reduced, the kidney-essence and blood decreased, as that the kidney network dystrophy cause the function of communicating exterior and interior, infiltrating blood and fluids, and excreting body wastes reduced which lead kidney network malnutrition and collateral disease generate. On the other hand, it cause the power of blood circulation down which lead turbid phlegm, blood stasis and pathogenic toxin obstruct the kidney network. While the renal collaterals is the key and the hub of qi and blood for renal nutrition.If renal collaterals is clear, qi and blood is sufficient, then the kidney function was to support the healthy and vigorous; if renal collaterals is not clear, qi and blood is deficiency, kidney failure is the failure to support. (3) The two which is asthenia of kidney and which is venation obstruction and toxic factors accumulating in tissue interact, reinforce each other:chronic renal failure disease process is various reasons causes kidney damaged, so we lost two division, San Jiao damaged, the function of separating the clear from turbid decreased, damp turbidity and uremia can not be eliminated from the body while accumulate in the body which lead to venation obstruction. In turn, toxic factors accumulating in tissue injury righteousness, block air machine, increase the network weakness, so on and so on, adding condition.2. The main treatment of chronic renal failure is nourishing the kidney as well as removing toxic materials and dredging collaterals according to the pathogenesis:TCM establish treatment principles according to etiology, pathogenesis and pathological changes. The basic pathogenesis of chronic renal failure is asthenia of kidney, venation obstruction and toxic factors accumulating in tissue, so the main treatment of chronic renal failure is nourishing the kidney as well as removing toxic materials and dredging collaterals. Relapse of chronic renal failure cause that its treatment focuses on both the root and branch aspects, supporting healthy qi and removing pathogenic factors. So as that we can tonify deficiency, activate the blood, dissolve phlegm and detoxication.3 Prescription basis and recipe analysis:Prescription of Bushen Jiedu Tongluo act representative for the Bushen Jiedu Tongluo recipe which consisting of:astragalus 30g, epimedium 20g, fructus corni 15g, salvia miltiorrhiza 30g, earthworm 15g, honeysuckle 15g, rhubarb 6g. Meanwhile, astragalus and epimedium is monarch drug for reinforcing kidney and qi. Fructus corni, salvia miltiorrhiza, earthworm and honeysuckle is ministerial drug for reinforcing kidney and qi, removing blood stasis, expelling miasma, freeing channel. Rhubarb is assistant and guide for clearing heat and expelling miasma, promoting blood circulation by removing blood stasis. All side effects for tonifying qi of the kidney, clearing away heat and toxic material, activating blood and dredging collaterals.
Experimental study Methods:The chronic renal failure rat models were caused by adenine according to literature method. The SPF-class male Wistar rats were randomly divided into two groups:normal control group and model group. After the success of modeling, the rats in model group were randomly divided into three groups:model control group、Niaoduqing group and Bushen Jiedu Tongluo group. After administration respectively,we observed BUN、Scr、transforming growth factorβ1、collagen typeⅠ、bone morphogenetic protein 7、TGFβ1mRNA、col-ImRNA and BMP-7mRNA. Results:1BUN and Scr:The points of BUN、Scr in the model group and treatment groups was higher significantly compared with the normal group(P<0.01).The points of BUN、Scr in the Niaoduqing group and Bushen Jiedu Tongluo group was decreased compared with model control group(P<0.01). The points of BUN in the Bushen Jiedu Tongluo group was decreased compared with Niaoduqing group (P<0.05), while the points of Scr between them had no significant difference(P>0.05).2Col-I protein: The expression of col-I in the model group, Niaoduqing group and Bushen Jiedu Tongluo group was increased compared with the normal group(P<0.01). The expression of col-I in the Niaoduqing group and Bushen Jiedu Tongluo group was decreased compared with the Model group (P<0.01). Bushen Jiedu Tongluo group and Niaoduqing group had significant difference (P<0.01, P<0.05).3 TGF-β1 protein:The expression of TGF-β1 in the Model group, Niaoduqing group and Bushen Jiedu Tongluo group was increased compared with the normal group(P<0.01). The expression of TGF-β1 in the Niaoduqing group and Bushen Jiedu Tongluo group was decreased compared with the Model group (P<0.01, P<0.05). Bushen Jiedu Tongluo group and Niaoduqing group had significant difference (P<0.01, P<0.05).4 BMP-7 protein:The expression of BMP-7 in the Model group, Niaoduqing group and Bushen Jiedu Tongluo group was decreased compared with the normal group(P<0.01). The expression of BMP-7 in the Niaoduqing group and Bushen Jiedu Tongluo group was increased compared with the Model group (P<0.01). Bushen Jiedu Tongluo group and Niaoduqing group had significant difference (P<0.01, P<0.05).5Col-ImRNA:The expression of Col-ImRNA in the Model group, Niaoduqing group and Bushen Jiedu Tongluo group was increased compared with the normal group(P<0.05). The expression of Col-ImRNA in the Niaoduqing group and Bushen Jiedu Tongluo group was decreased compared with the Model group (P<0.05). Bushen Jiedu Tongluo group and Niaoduqing group had significant difference (P<0.05).6TGF-β1mRNA:The expression of TGF-β1mRNA in the Model group, Niaoduqing group and Bushen Jiedu Tongluo group was increased compared with the normal group(P<0.05). The expression of TGF-β1mRNA in the Niaoduqing group and Bushen Jiedu Tongluo group was decreased compared with the Model group (P<0.05). Bushen Jiedu Tongluo group and Niaoduqing group had significant difference (P<0.05).7BMP-7mRNA:The expression of BMP-7mRNA in the Model group, Niaoduqing group and Bushen Jiedu Tongluo group was decreased compared with the normal group(P<0.05). The expression of BMP-7mRNA in the Niaoduqing group and Bushen Jiedu Tongluo group was increased compared with the Model group (P<0.05). Bushen Jiedu Tongluo group and Niaoduqing group had significant difference(P<0.05). Conclusion lBushen Jiedu Tongluo recipe could reduce renal function in rats with chronic renal failure.2 Bushen Jiedu Tongluo recipe could reduce the pathological damage in rats with chronic renal failure, and it was better than Niaoduqing.3 Bushen Jiedu Tongluo recipe could alleviate chronic renal failure and reduce the renal interstitial fibrosis by reducing the expression of Col-I、TGF-β1、Col-I mRNA and TGF-β1mRNA, increasing the expression of BMP-7 and BMP-7mRNA.4 The side of expression of Col-I、TGF-β1、BMP-7、Col-I mRNA、TGF-β1mRNA and BMP-7mRNA effected by Bushen Jiedu Tongluo recipe was better than its by Niaoduqing.
引文
[1]程小霞,王永钧.中药抗氧化合剂治疗慢性肾小球肾炎临床观察[J].中医杂志,1996,37(9)：542.
[2]张翠.温补脾肾、泄浊化瘀药对慢性肾功能衰竭患者CD44,CD54,TNF-α表达调节的影响[J].中国中药杂志.2007.32(2)：140-142.
[3]李先锋.自拟益肾排毒汤治疗慢性肾功能衰竭29例.职业与健康.2008.24(9)：905.
[4]Bothle A, Muller GA, Wehrmann M, et al. Pathgenesis of chronic renal failure in the primary glomerulopathies, renal vasculopat-hies, and chronic interstitial nephrit ides [J]. Kidney Int,1996,49:54.
[5]Gonalez Cuadrado S, Lorz C, Moral RG, et al. Agones tic anti-Fas antibodies induce glome ruler cell apoptosis in mice in vivo [J].Kidney Int,1997,51:1739-1746.
[6]Utimurs R,Fujihara CK,Matter AL, et al.Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int,2003,63(1):209-216.
[7]Choi ME, Kim EG, Huang Q, et al.Rat mesangial cell hypertrophy in response to transforming growth factor-β1 [J]. Kidney Int,1993, 43(5):948-958.
[8]TAKAYUKI SUZUKI, MASATO KIMURA, MITSUKO ASANO, et al. Role of atrophic tubules in development of interstitial fibrosis in microembolism-induced renal failure in rat [J]. Am J Pathol,2001, 158(1):75-85.
[9]Guo G,Morrissery J,McCracken R, et al. Contributions of angiotensin Ⅱ and tumor necrosis factor alpha to the develop-ment of renalfibrosis[J].Am J physiol,2001,280(5):777-785.
[10]Ruiz-Ortega M, Egido J. Angiotensin Ⅱ modulates cellgrowth-relatelated events and synthesis of matrix proteinsin renam interstitial fibroblasts[J]. Kidney Int,1997,52 (6):1497-1510.
[11]Hocher B,Thone-Reineke C,RohmeissP, et al.Endothelin-1 transgenic mice develop glome ruloscle-rosis, interstitial fibrosis,and renal cysts but not hypertension[J]. J Clininvest, 1997,99 (6):1380-1389.
[12]Guo G, Morrissery J, McCracken R, et al. Contributions of angiotensin Ⅱ and tumornecrosis factor alpha to the develop-ment of renalfibrosis[J].Am J physiol,2001,280(5):777-785.
[13]李艳秋,粟霄立,王力宁,等.中性粒细胞集落刺激因子基因多态性与SLE的相关性的研究[J].中华风湿病学杂志,2006,10(9)：517-521.
[14]刘冠贤,叶任高,谭志明,等.大黄素延缓狼疮性肾炎肾间质纤维化作用的研究[J].中国实验临床免疫学,1999,11(3)：24.
[15]Alan Cass. Kidney disease:are you at risk[J].The Medical Journal of Australia June.2002,176 (11):515-516.
[16]蒋季杰,范亚平.慢性肾功能衰竭的发病机理和对策[J].中华肾脏病杂志,1994,10(3)：174-177.
[17]章友康,耿琳,王海燕等应用免疫电镜技术研究人类肾小球结构成份[J].中华肾脏病杂志,1992,8：35
[18]周春华,章友康,王海燕等免疫电镜技术研究肾小球硬化过程中细胞外基质的变化[J].中华肾脏病杂志,1995,11(增刊)：21
[19]Mohammed S,Taguehi T. Cellular and molecular events leading to renal tubulointerstitial fibrosis[J].Med Electron Mierose, 2002,35:68-80
[20]Kliem V, Johnson RJ, Aloers CE, et al. Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats[J]. Kidney Int,1996,49:666～678
[21]Dhalla AK,Kandala JC,Weber KT, et al. Identification of negative and positive regulatory elements in the ratal(Ⅰ)collagen gene promoter[J]. Int J Biochem Cell Biol,1997,29:143
[22]Heldin CH,Miyazono K, Ten Dijke P. TGF-beta signal-ling from cell membrane to nucleus through SMAD pro-teins[J]. Nature,1997, 390(3):465
[23]Saulo K, Jeremiah M. New approaches to delay the pro-gress ion of chronic renal failure [J]. Kidney Int,2002,61 (Suppl80):S23
[24]郑平东,朱燕俐,丁名城,等.用腺嘌嫦制慢性肾衰竭动物模型[J].中华肾脏病杂志,1989,5(6)：342-344.
[25]邓虹珠,金伟军,等.慢性肾衰竭药效学研究的设计和方法[J].中国中药杂志,1998,23(4)：243-246.
[26]周小舟,张盛光,阳晓,等.腺嘌呤所致大鼠慢性肾功能衰竭的机理研究[J].基础医学与临床,1997,17(1)：54-57.
[27]Yokozawa T, Zheng PD, Oura H, et al. Animal model of adenine induced chronic renal failure in rats [J]. Nephron1986,44(3):230-234.
[28]陈清江,杨丽,王辉,等.黄芪对人肾间质成纤维细胞增殖和转化因子-β 1mRNA表达的影响[J].郑州大学学报(医学版),2005,40(5)：871-873.
[29]杨蓉,倪兆慧,钱家麒,等.人类转化生长因子β诱导基因-克隆3在糖尿病大鼠肾组织中的表达以及洛沙坦和黄芪对其影响[J].中华肾脏病杂志,2004,20(5)：347-350.
[30]程庆砾,陈香美,师锁柱,等.中药淫羊藿对慢性肾衰大鼠免疫病理及细胞外基质的影响[J].中华内科杂志,1994,33(2)：83
[31]程庆砾,师锁柱,廖洪军.淫羊藿对5／6肾功能大鼠细胞免疫功能的影响[J].中国中西医给合杂志,1993,13(特)：28
[32]梁恒,邢建宇,刘希成,等。山茱萸作用鼠IgA肾病的肾组织差异蛋白质谱[J].西安交通大学学报,2005,6(24)
[33]李春香,张艳玲,顾连方.丹参对慢性肾衰竭大鼠肾脏细胞凋亡及 Fas-Fas1表达的影响[J].中国中西医结合肾病杂志,2002,3(2)：101-102.
[34]高春梅,杜跃中,潘晓鹏,等.金银花药理作用的研究进展及应用[J].人参研究,2007,4(4)
[35]张佩青,朱勇志,迟继铭,等.临床中医家张琪分册[M].中国中医药出版社,2003,43-45
[1]张镜人.慢性肾功能不全的证治探讨[J].上海中医药杂志,1982,(2)：11.
[2]沈庆法.慢性肾功能衰竭的研究与展望[J].中医杂志,1988,(4)65-66.
[3]林启展,徐大基,马育鹏.张琪治疗慢性肾功能衰竭经验[J].中医杂志,2006,47(8)：576.
[4]张勉之.张大宁诊治慢性肾功能衰竭的思路与方法[J].中医杂志,2007,48(9)：846.
[5]郑金发,李力辉.李焘老师治疗慢性肾功能衰竭经验举隅[J].甘肃中医,2008,21(4)
[6]刘丙欣.运用络病理论辨治慢性肾功能衰竭解析[J].中医药学刊,2005,23(3)：505-506.
[7]栾雷.慢性肾衰关乎少阳阳明[J].辽宁中医杂志,2005,32(2)：112-113.
[8]焦安钦,傅兴兰.慢性肾衰的病机特点和治疗对策[J].山东中医药大学学报,2001,25(2)：90-92.
[9]洪钦国,朱光辉.慢性肾功能衰竭的中医治疗[J].新中医,2007,39(1)：89.
[10]高建东,王琛,侯卫国.郑平东治疗慢性肾功能衰竭经验[J].中医杂志,2008,49(6)：498.
[11]李准亿,李舜华.辨证治疗慢性肾功能衰竭[J].发现(增刊),2007：116-117.
[12]郭石宏,侯国华.慢性肾功能衰竭的分期论治[J].山西中医,2006,22(1)：60-61.
[13]石显方,傅文录.石景亮教授治疗慢性肾功能衰竭的经验[J].四川中医,2006,24(1)：1-2.
[14]王立新,杨霓芝,赵代鑫,等.益气活血蠲毒法治疗慢性肾功能衰竭90例临床观察[J].辽宁中医杂志,2008,35(1)：63-65.
[15]李湘萍.益气温阳活血法治疗慢性肾功能衰竭临床观察[J].山西医药杂志,2007,36(5)：351-352.
[16]刘敏,姚素梅,秦艳荣.中医治疗慢性肾功能衰竭33例临床观察[J].河南大学学报(医学版),2006,25(3)：60-62.
[17]王刚,郭晓玲,阎圣玺.保肾冲剂治疗慢性肾功能衰竭34例[J].陕西中医,2006,27(12)：1478-1481.
[18]姜竹成.癸康宝对慢性肾功能衰竭气阴两虚证早期干预作用的临床与实验研究[J].山东中医药大学,2007.
[19]王东海,韩亮,高运.海昆肾喜胶囊治疗慢性肾功能衰竭近期疗效观察[J].中国医药,2007,2(3)：172-173.
[20]闫新爱.肾衰1号方治疗慢性肾功能衰竭的临床研究[J].山东中医药大学,2009,09-17.
[21]谷红东.大黄汤灌肠治疗慢性肾功能衰竭的临床观察与护理[J].国际护理学杂志,2007,26(1)：40-41.
[22]董建国,孙文华,王菁.附子泻心汤灌肠治疗慢性肾功能衰竭56例[J].河南中医,2008,28(5)：3.
[23]兰芝林.中药药浴治疗慢性肾衰30例[J].四川中医,2001,19(8)：5023.
[24]孙亚臣,孙劲秋.中药肾区热敷疗法治疗慢性肾功能衰竭40例临床观[J].辽宁中医杂志,2005,32(11)：1165-1166.
[25]巴元明,霍长亮,许小泰.保肾膏三伏穴位敷贴治疗慢性肾功能衰竭30例临床观察[J].中医杂志,2005,46(10)：747.
[26]赵志新.中药离子导入治疗慢性肾衰竭的临床观察[J].护理研究,2006,20(8)：2191.
[27]王晓玲,王俭勤,夏延龄,等.大黄素对人肾成纤维细胞抑制作用的研究[J].中国中西医结合肾病杂志,2002,3(11)：629.
[28]张杰,屈燧林,王剑勤.大黄素对血管紧张素Ⅱ刺激人肾成纤维细胞增殖、胶原表达的抑制效应研究[J].四川医学,2002,23(11)：1114.
[29]魏建冬,黎磊石,姚建.大黄治疗大鼠系膜增殖性肾炎的实验研究[J].中华内科杂志,1997,36(2)：87.
[30]王要军,孙自勤,权启镇,等.冬虫夏草对入成纤维细胞形态及细胞外基质合成功能的影响[J].滨州医学院学报,1999,22(3)：226-227.
[31]王要军,权启镇,孙自勤,等.冬虫夏草对人成纤维细胞ICAM-1及CD126表达的影响[J].滨州医学院学报,1999,22(4)：316-317.
[32]袁继丽,刘成,刘成海,等.冬虫夏草治疗肾纤维化研究进展[J].中国中西医结合肾病杂志,2004,5(2)：121-124.
[33]刘海燕,陈孝文,刘华锋,等.三七总甙对尿毒血清诱导的HK-2细胞增殖及总胶原分泌的影响[J].中国中西医结合肾病杂志,2004,5(3)：143-145.
[34]刘海燕,陈孝文,刘华锋,等.三七总甙对尿毒血清诱导的人肾小管上皮细胞TGF-β1、CTGF基因表达和蛋白分泌的影响[J].中国药理学通报,2005,21(11)：1366-1370.
[35]张国强,叶任高,孔庆瑜,等.三七总甙诱导间质纤维化人肾成纤维细胞凋亡及其分子机理初探[J].中华肾脏病杂志,1998,14(2)：B93.
[36]杨志云,马琼英.丹参注射液对肾小球系膜细胞增殖及产生IL-6、Ⅳ型胶原影响的实验研究[J].中国中西医结合肾病杂志,2001,2(7)：420-421.
[37]林琼真,于洁,邓英辉,等.丹参注射液对大鼠梗阻性肾间质纤维化的保护作用[J].中国中西医结合肾病杂志,2003,4(2)：71-73.
[38]王亚平,李伯祥.川芎嗪防治肾间质纤维化作用的实验研究[J].中国中西医结合肾病杂志,2002,3(2)：77-78.
[39]孙林,易著文,虞佩兰.川芎嗪对人胎肾小球系膜细胞增殖的影响及其机理探讨[J].中国中西医结合杂志,1995,15(3)：134-136.
[40]杜兰萍,胡仲仪,邓跃毅,等.莪术对肾脏外细胞基质影响的实验研究[J].上海中医药杂志,2001,22(6)：386.
[41]陶松桔,尹支农,徐自强,等.黄芪注射液对糖尿病肾病患者血型胶原 与转化生长因子-β水平的影响及其意义[J].中国综合临床,2004,29(3)：217-219.
[42]杨红霞,朱敏怡.黄芪对糖尿病大鼠肾组织的保护作用[J].实用医学杂志,2005,21(17)：1964-1965.
[43]YangJ, ChenS, HuangL, etal. SustaineddepressionofnakedplasmidDN Aencodinghepotocytegrowthfactorinmicepro-motesliverandoverallbo dygrowth[J]. Hepotology,2001,83:848-859.
[44]牟娜,张庆怡,倪兆慧,等·黄芪对高糖作用下肾间质成纤维细胞表达HGF的影响[J].中国中西医结合肾病杂志,2002,3(1)：7.
[45]薄守波,鞠建伟,李建远,等.褐藻多糖硫酸酯对人肾小球系膜细胞增殖及纤连蛋白与转化生长因子分泌的影响[J].中华肾脏病杂志,2006,22(10)：638-639.
[46]李伯祥,张雪光.a-平滑肌肌动蛋白在大鼠肾间质损伤时的表达及红景天贰的保护作用[J].中华肾脏病杂志,2000,16(2)：118-120.
[47]尹莲芳,刘璐,弓玉祥,等.黄蜀葵花对肾病综合征模型大鼠小管损伤保护作用的研究[J].首都医科大学学报,2000,21(3)：209.
[48]尹莲芳,刘璐,弓玉祥,等.中药黄蜀葵花对肾病大鼠尿中透明质酸的影响[J].新中医,2000,32(9)：32.
[49]王钊林,马华.中药芪红合剂对肾间质纤维化模型大鼠肾皮质中bcl-2表达的影响[J].山西中医学院学报,2006,7(4)：17.
[50]韩琳,陈志强,范焕芳,等.鳖甲煎丸对肾间质纤维化模型大鼠肾脏的保护作用[J].北京中医药大学学报,2007,30(4)：262.
[51]何立群,高建东,郑平东.抗纤灵冲剂对成纤维细胞增殖及分泌ECM与TNF-a的影响汇[J].中国中西医结合肾病杂志,2001,2(9)：511-514.
[52]邓英辉,于洁,林琼真,等.灯盏细辛注射液对大鼠肾间质纤维化的影响[J].中国中西医结合杂志,2008,28(2)：142.
[53]宦红娣,张景红,郑士荣,等.地灵丹汤对单侧输尿管梗阻大鼠模型肾间质纤维化的防治作用[J].中西医结合学报,2008,6(5)：493.
[54]王清兰,袁继丽,陶艳艳,等.扶正化瘀方抗肾间质纤维化作用机理的研究[J].药品评价,2008,5(5)：209.
[55]马丽娟,杨汝春,鲁盈,等.复方积雪草对UUO小鼠肾组织细胞转分化与肾纤维化的影响[J].浙江中医药大学学报,2006,30(6)：614.
[56]王永钧.治疗慢性肾功能衰竭实践和体会[J].浙江中医学院学报,2003,27(2)：1-4.
[57]于俊生,刘海军,刘先英,等.和络泄浊方对肾纤维化大鼠肾组织α-SMA、Ⅳ型胶原表达的影响[J].中国中医基础医学杂志,2008,14(2)：108.
[58]于俊生,刘丙欣.和络泄浊方对肾间质纤维化大鼠转化生长因子β1表达的影响[J].中医药学刊,2006,24(7)：1220.
[59]孟立强,屈磊,李晓玫.黄芪当归合剂对肾间质纤维化的多靶点抑制作用[J].中国药理学通报,2006,22(3)：296.
[60]姚钢炼,宁宁,廖婷婷,等.苦楂合剂对大鼠梗阻性肾间质纤维化的保护作用[J].陕西中医,2007,28(4)：504.
[61]丁跃玲,赵玉庸,陈志强,等.肾络通对阿霉素肾病大鼠肾小管间质增殖细胞核抗原表达的影响[J].中国中医基础医学杂志,2004,10(1)：48-50.
[62]陈志强,王月华,丁英钧,等.肾络通对肾间质纤维化实验大鼠病理及基质金属蛋白酶系统的影响[J].北京中医药大学学报,2006,29(1)：23-26.
[1]肖惟丹.补肾解毒通络方对肾间质纤维化大鼠TGF-β1、BMP-7表达的影响[J].辽宁中医药大学学报,2010,12(10).
[2]肖惟丹.补肾解毒通络方对慢性肾衰大鼠的实验研究[J].云南中医中药杂志,2010,5.
[2]张翠.温补脾肾、泄浊化瘀药对慢性肾功能衰竭患者CD44,CD54,TNF-α表达调节的影响[J].中国中药杂志.2007.32(2)：140-142.
[3]李先锋.自拟益肾排毒汤治疗慢性肾功能衰竭29例.职业与健康.2008.24(9)：905.
[4]Bothle A, Muller GA, Wehrmann M, et al. Pathgenesis of chronic renal failure in the primary glomerulopathies, renal vasculopat-hies, and chronic interstitial nephrit ides [J]. Kidney Int,1996,49:54.
[5]Gonalez Cuadrado S, Lorz C, Moral RG, et al. Agones tic anti-Fas antibodies induce glome ruler cell apoptosis in mice in vivo [J].Kidney Int,1997,51:1739-1746.
[6]Utimurs R,Fujihara CK,Matter AL, et al.Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int,2003,63(1):209-216.
[7]Choi ME, Kim EG, Huang Q, et al.Rat mesangial cell hypertrophy in response to transforming growth factor-β1 [J]. Kidney Int,1993, 43(5):948-958.
[8]TAKAYUKI SUZUKI, MASATO KIMURA, MITSUKO ASANO, et al. Role of atrophic tubules in development of interstitial fibrosis in microembolism-induced renal failure in rat [J]. Am J Pathol,2001, 158(1):75-85.
[9]Guo G,Morrissery J,McCracken R, et al. Contributions of angiotensin Ⅱ and tumor necrosis factor alpha to the develop-ment of renalfibrosis[J].Am J physiol,2001,280(5):777-785.
[10]Ruiz-Ortega M, Egido J. Angiotensin Ⅱ modulates cellgrowth-relatelated events and synthesis of matrix proteinsin renam interstitial fibroblasts[J]. Kidney Int,1997,52 (6):1497-1510.
[11]Hocher B,Thone-Reineke C,RohmeissP, et al.Endothelin-1 transgenic mice develop glome ruloscle-rosis, interstitial fibrosis,and renal cysts but not hypertension[J]. J Clininvest, 1997,99 (6):1380-1389.
[12]Guo G, Morrissery J, McCracken R, et al. Contributions of angiotensin Ⅱ and tumornecrosis factor alpha to the develop-ment of renalfibrosis[J].Am J physiol,2001,280(5):777-785.
[13]李艳秋,粟霄立,王力宁,等.中性粒细胞集落刺激因子基因多态性与SLE的相关性的研究[J].中华风湿病学杂志,2006,10(9)：517-521.
[14]刘冠贤,叶任高,谭志明,等.大黄素延缓狼疮性肾炎肾间质纤维化作用的研究[J].中国实验临床免疫学,1999,11(3)：24.
[15]Alan Cass. Kidney disease:are you at risk[J].The Medical Journal of Australia June.2002,176 (11):515-516.
[16]蒋季杰,范亚平.慢性肾功能衰竭的发病机理和对策[J].中华肾脏病杂志,1994,10(3)：174-177.
[17]章友康,耿琳,王海燕等应用免疫电镜技术研究人类肾小球结构成份[J].中华肾脏病杂志,1992,8：35
[18]周春华,章友康,王海燕等免疫电镜技术研究肾小球硬化过程中细胞外基质的变化[J].中华肾脏病杂志,1995,11(增刊)：21
[19]Mohammed S,Taguehi T. Cellular and molecular events leading to renal tubulointerstitial fibrosis[J].Med Electron Mierose, 2002,35:68-80
[20]Kliem V, Johnson RJ, Aloers CE, et al. Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats[J]. Kidney Int,1996,49:666～678
[21]Dhalla AK,Kandala JC,Weber KT, et al. Identification of negative and positive regulatory elements in the ratal(Ⅰ)collagen gene promoter[J]. Int J Biochem Cell Biol,1997,29:143
[22]Heldin CH,Miyazono K, Ten Dijke P. TGF-beta signal-ling from cell membrane to nucleus through SMAD pro-teins[J]. Nature,1997, 390(3):465
[23]Saulo K, Jeremiah M. New approaches to delay the pro-gress ion of chronic renal failure [J]. Kidney Int,2002,61 (Suppl80):S23
[24]郑平东,朱燕俐,丁名城,等.用腺嘌嫦制慢性肾衰竭动物模型[J].中华肾脏病杂志,1989,5(6)：342-344.
[25]邓虹珠,金伟军,等.慢性肾衰竭药效学研究的设计和方法[J].中国中药杂志,1998,23(4)：243-246.
[26]周小舟,张盛光,阳晓,等.腺嘌呤所致大鼠慢性肾功能衰竭的机理研究[J].基础医学与临床,1997,17(1)：54-57.
[27]Yokozawa T, Zheng PD, Oura H, et al. Animal model of adenine induced chronic renal failure in rats [J]. Nephron1986,44(3):230-234.
[28]陈清江,杨丽,王辉,等.黄芪对人肾间质成纤维细胞增殖和转化因子-β 1mRNA表达的影响[J].郑州大学学报(医学版),2005,40(5)：871-873.
[29]杨蓉,倪兆慧,钱家麒,等.人类转化生长因子β诱导基因-克隆3在糖尿病大鼠肾组织中的表达以及洛沙坦和黄芪对其影响[J].中华肾脏病杂志,2004,20(5)：347-350.
[30]程庆砾,陈香美,师锁柱,等.中药淫羊藿对慢性肾衰大鼠免疫病理及细胞外基质的影响[J].中华内科杂志,1994,33(2)：83
[31]程庆砾,师锁柱,廖洪军.淫羊藿对5／6肾功能大鼠细胞免疫功能的影响[J].中国中西医给合杂志,1993,13(特)：28
[32]梁恒,邢建宇,刘希成,等。山茱萸作用鼠IgA肾病的肾组织差异蛋白质谱[J].西安交通大学学报,2005,6(24)
[33]李春香,张艳玲,顾连方.丹参对慢性肾衰竭大鼠肾脏细胞凋亡及 Fas-Fas1表达的影响[J].中国中西医结合肾病杂志,2002,3(2)：101-102.
[34]高春梅,杜跃中,潘晓鹏,等.金银花药理作用的研究进展及应用[J].人参研究,2007,4(4)
[35]张佩青,朱勇志,迟继铭,等.临床中医家张琪分册[M].中国中医药出版社,2003,43-45
[1]张镜人.慢性肾功能不全的证治探讨[J].上海中医药杂志,1982,(2)：11.
[2]沈庆法.慢性肾功能衰竭的研究与展望[J].中医杂志,1988,(4)65-66.
[3]林启展,徐大基,马育鹏.张琪治疗慢性肾功能衰竭经验[J].中医杂志,2006,47(8)：576.
[4]张勉之.张大宁诊治慢性肾功能衰竭的思路与方法[J].中医杂志,2007,48(9)：846.
[5]郑金发,李力辉.李焘老师治疗慢性肾功能衰竭经验举隅[J].甘肃中医,2008,21(4)
[6]刘丙欣.运用络病理论辨治慢性肾功能衰竭解析[J].中医药学刊,2005,23(3)：505-506.
[7]栾雷.慢性肾衰关乎少阳阳明[J].辽宁中医杂志,2005,32(2)：112-113.
[8]焦安钦,傅兴兰.慢性肾衰的病机特点和治疗对策[J].山东中医药大学学报,2001,25(2)：90-92.
[9]洪钦国,朱光辉.慢性肾功能衰竭的中医治疗[J].新中医,2007,39(1)：89.
[10]高建东,王琛,侯卫国.郑平东治疗慢性肾功能衰竭经验[J].中医杂志,2008,49(6)：498.
[11]李准亿,李舜华.辨证治疗慢性肾功能衰竭[J].发现(增刊),2007：116-117.
[12]郭石宏,侯国华.慢性肾功能衰竭的分期论治[J].山西中医,2006,22(1)：60-61.
[13]石显方,傅文录.石景亮教授治疗慢性肾功能衰竭的经验[J].四川中医,2006,24(1)：1-2.
[14]王立新,杨霓芝,赵代鑫,等.益气活血蠲毒法治疗慢性肾功能衰竭90例临床观察[J].辽宁中医杂志,2008,35(1)：63-65.
[15]李湘萍.益气温阳活血法治疗慢性肾功能衰竭临床观察[J].山西医药杂志,2007,36(5)：351-352.
[16]刘敏,姚素梅,秦艳荣.中医治疗慢性肾功能衰竭33例临床观察[J].河南大学学报(医学版),2006,25(3)：60-62.
[17]王刚,郭晓玲,阎圣玺.保肾冲剂治疗慢性肾功能衰竭34例[J].陕西中医,2006,27(12)：1478-1481.
[18]姜竹成.癸康宝对慢性肾功能衰竭气阴两虚证早期干预作用的临床与实验研究[J].山东中医药大学,2007.
[19]王东海,韩亮,高运.海昆肾喜胶囊治疗慢性肾功能衰竭近期疗效观察[J].中国医药,2007,2(3)：172-173.
[20]闫新爱.肾衰1号方治疗慢性肾功能衰竭的临床研究[J].山东中医药大学,2009,09-17.
[21]谷红东.大黄汤灌肠治疗慢性肾功能衰竭的临床观察与护理[J].国际护理学杂志,2007,26(1)：40-41.
[22]董建国,孙文华,王菁.附子泻心汤灌肠治疗慢性肾功能衰竭56例[J].河南中医,2008,28(5)：3.
[23]兰芝林.中药药浴治疗慢性肾衰30例[J].四川中医,2001,19(8)：5023.
[24]孙亚臣,孙劲秋.中药肾区热敷疗法治疗慢性肾功能衰竭40例临床观[J].辽宁中医杂志,2005,32(11)：1165-1166.
[25]巴元明,霍长亮,许小泰.保肾膏三伏穴位敷贴治疗慢性肾功能衰竭30例临床观察[J].中医杂志,2005,46(10)：747.
[26]赵志新.中药离子导入治疗慢性肾衰竭的临床观察[J].护理研究,2006,20(8)：2191.
[27]王晓玲,王俭勤,夏延龄,等.大黄素对人肾成纤维细胞抑制作用的研究[J].中国中西医结合肾病杂志,2002,3(11)：629.
[28]张杰,屈燧林,王剑勤.大黄素对血管紧张素Ⅱ刺激人肾成纤维细胞增殖、胶原表达的抑制效应研究[J].四川医学,2002,23(11)：1114.
[29]魏建冬,黎磊石,姚建.大黄治疗大鼠系膜增殖性肾炎的实验研究[J].中华内科杂志,1997,36(2)：87.
[30]王要军,孙自勤,权启镇,等.冬虫夏草对入成纤维细胞形态及细胞外基质合成功能的影响[J].滨州医学院学报,1999,22(3)：226-227.
[31]王要军,权启镇,孙自勤,等.冬虫夏草对人成纤维细胞ICAM-1及CD126表达的影响[J].滨州医学院学报,1999,22(4)：316-317.
[32]袁继丽,刘成,刘成海,等.冬虫夏草治疗肾纤维化研究进展[J].中国中西医结合肾病杂志,2004,5(2)：121-124.
[33]刘海燕,陈孝文,刘华锋,等.三七总甙对尿毒血清诱导的HK-2细胞增殖及总胶原分泌的影响[J].中国中西医结合肾病杂志,2004,5(3)：143-145.
[34]刘海燕,陈孝文,刘华锋,等.三七总甙对尿毒血清诱导的人肾小管上皮细胞TGF-β1、CTGF基因表达和蛋白分泌的影响[J].中国药理学通报,2005,21(11)：1366-1370.
[35]张国强,叶任高,孔庆瑜,等.三七总甙诱导间质纤维化人肾成纤维细胞凋亡及其分子机理初探[J].中华肾脏病杂志,1998,14(2)：B93.
[36]杨志云,马琼英.丹参注射液对肾小球系膜细胞增殖及产生IL-6、Ⅳ型胶原影响的实验研究[J].中国中西医结合肾病杂志,2001,2(7)：420-421.
[37]林琼真,于洁,邓英辉,等.丹参注射液对大鼠梗阻性肾间质纤维化的保护作用[J].中国中西医结合肾病杂志,2003,4(2)：71-73.
[38]王亚平,李伯祥.川芎嗪防治肾间质纤维化作用的实验研究[J].中国中西医结合肾病杂志,2002,3(2)：77-78.
[39]孙林,易著文,虞佩兰.川芎嗪对人胎肾小球系膜细胞增殖的影响及其机理探讨[J].中国中西医结合杂志,1995,15(3)：134-136.
[40]杜兰萍,胡仲仪,邓跃毅,等.莪术对肾脏外细胞基质影响的实验研究[J].上海中医药杂志,2001,22(6)：386.
[41]陶松桔,尹支农,徐自强,等.黄芪注射液对糖尿病肾病患者血型胶原 与转化生长因子-β水平的影响及其意义[J].中国综合临床,2004,29(3)：217-219.
[42]杨红霞,朱敏怡.黄芪对糖尿病大鼠肾组织的保护作用[J].实用医学杂志,2005,21(17)：1964-1965.
[43]YangJ, ChenS, HuangL, etal. SustaineddepressionofnakedplasmidDN Aencodinghepotocytegrowthfactorinmicepro-motesliverandoverallbo dygrowth[J]. Hepotology,2001,83:848-859.
[44]牟娜,张庆怡,倪兆慧,等·黄芪对高糖作用下肾间质成纤维细胞表达HGF的影响[J].中国中西医结合肾病杂志,2002,3(1)：7.
[45]薄守波,鞠建伟,李建远,等.褐藻多糖硫酸酯对人肾小球系膜细胞增殖及纤连蛋白与转化生长因子分泌的影响[J].中华肾脏病杂志,2006,22(10)：638-639.
[46]李伯祥,张雪光.a-平滑肌肌动蛋白在大鼠肾间质损伤时的表达及红景天贰的保护作用[J].中华肾脏病杂志,2000,16(2)：118-120.
[47]尹莲芳,刘璐,弓玉祥,等.黄蜀葵花对肾病综合征模型大鼠小管损伤保护作用的研究[J].首都医科大学学报,2000,21(3)：209.
[48]尹莲芳,刘璐,弓玉祥,等.中药黄蜀葵花对肾病大鼠尿中透明质酸的影响[J].新中医,2000,32(9)：32.
[49]王钊林,马华.中药芪红合剂对肾间质纤维化模型大鼠肾皮质中bcl-2表达的影响[J].山西中医学院学报,2006,7(4)：17.
[50]韩琳,陈志强,范焕芳,等.鳖甲煎丸对肾间质纤维化模型大鼠肾脏的保护作用[J].北京中医药大学学报,2007,30(4)：262.
[51]何立群,高建东,郑平东.抗纤灵冲剂对成纤维细胞增殖及分泌ECM与TNF-a的影响汇[J].中国中西医结合肾病杂志,2001,2(9)：511-514.
[52]邓英辉,于洁,林琼真,等.灯盏细辛注射液对大鼠肾间质纤维化的影响[J].中国中西医结合杂志,2008,28(2)：142.
[53]宦红娣,张景红,郑士荣,等.地灵丹汤对单侧输尿管梗阻大鼠模型肾间质纤维化的防治作用[J].中西医结合学报,2008,6(5)：493.
[54]王清兰,袁继丽,陶艳艳,等.扶正化瘀方抗肾间质纤维化作用机理的研究[J].药品评价,2008,5(5)：209.
[55]马丽娟,杨汝春,鲁盈,等.复方积雪草对UUO小鼠肾组织细胞转分化与肾纤维化的影响[J].浙江中医药大学学报,2006,30(6)：614.
[56]王永钧.治疗慢性肾功能衰竭实践和体会[J].浙江中医学院学报,2003,27(2)：1-4.
[57]于俊生,刘海军,刘先英,等.和络泄浊方对肾纤维化大鼠肾组织α-SMA、Ⅳ型胶原表达的影响[J].中国中医基础医学杂志,2008,14(2)：108.
[58]于俊生,刘丙欣.和络泄浊方对肾间质纤维化大鼠转化生长因子β1表达的影响[J].中医药学刊,2006,24(7)：1220.
[59]孟立强,屈磊,李晓玫.黄芪当归合剂对肾间质纤维化的多靶点抑制作用[J].中国药理学通报,2006,22(3)：296.
[60]姚钢炼,宁宁,廖婷婷,等.苦楂合剂对大鼠梗阻性肾间质纤维化的保护作用[J].陕西中医,2007,28(4)：504.
[61]丁跃玲,赵玉庸,陈志强,等.肾络通对阿霉素肾病大鼠肾小管间质增殖细胞核抗原表达的影响[J].中国中医基础医学杂志,2004,10(1)：48-50.
[62]陈志强,王月华,丁英钧,等.肾络通对肾间质纤维化实验大鼠病理及基质金属蛋白酶系统的影响[J].北京中医药大学学报,2006,29(1)：23-26.
[1]肖惟丹.补肾解毒通络方对肾间质纤维化大鼠TGF-β1、BMP-7表达的影响[J].辽宁中医药大学学报,2010,12(10).
[2]肖惟丹.补肾解毒通络方对慢性肾衰大鼠的实验研究[J].云南中医中药杂志,2010,5.